Market Research Industry Reports

Mild Cognitive Impairment - Pipeline Review, H2 2018

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Mild Cognitive Impairment - Pipeline Review, H2 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Mild Cognitive Impairment - Pipeline Review, H2 2018, provides an overview of the Mild Cognitive Impairment (Central Nervous System) pipeline landscape.

Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Symptoms include depression, irritability and aggression, anxiety and apathy. Risk factors include diabetes, high blood pressure, and depression, smoking and elevated cholesterol.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Mild Cognitive Impairment - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Mild Cognitive Impairment (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 11, 2, 1 and 9 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Mild Cognitive Impairment (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Mild Cognitive Impairment (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Mild Cognitive Impairment (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Mild Cognitive Impairment (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Mild Cognitive Impairment (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Mild Cognitive Impairment - Overview
Mild Cognitive Impairment - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Mild Cognitive Impairment - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Mild Cognitive Impairment - Companies Involved in Therapeutics Development
AbbVie Inc
AgeneBio Inc
Avraham Pharmaceuticals Ltd
Biogen Inc
CereSpir Inc
Eisai Co Ltd
Eli Lilly and Co
IntelGenx Corp
Neuron Biopharma SA
Octapharma AG
Pfizer Inc
Sage Therapeutics Inc
SBI Pharmaceuticals Co Ltd
Therapix Biosciences Ltd
Mild Cognitive Impairment - Drug Profiles
ABBV-8E12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aminolevulinic acid hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAN-2401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bosutinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brexanolone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DAOI-B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elenbecestat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gosuranemab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
itanapraced - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ladostigil tartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
levetiracetam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
levofacetoperane - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3303560 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
montelukast sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MW-151 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPS-0158 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPS-0163 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NST-0037 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NST-0076 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NST-0078 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAM-38 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Agonize Insulin Receptor for Mild Cognitive Impairment and Alzheimers Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sargramostim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit EIF2AK2 for Mild Cognitive Impairment - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GABRA5 for CNS Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THX-130 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mild Cognitive Impairment - Dormant Projects
Mild Cognitive Impairment - Discontinued Products
Mild Cognitive Impairment - Product Development Milestones
Featured News & Press Releases
Sep 27, 2017: Therapixs First-in-Class Therapy Demonstrates Reversal of Age-Related Cognitive Impairment in Pre-Clinical Study
Oct 31, 2016: Therapix Biosciences Successfully Completed the Development of a Formulation for a Tablet for Sublingual Administration of THC for Pharmaceutical Use
Aug 22, 2016: IntelGenx Announces Successful Clinical Study for Montelukast for the Treatment of Degenerative Diseases of the Brain
Jul 13, 2016: IntelGenx to Initiate Phase 1 Trial of Montelukast
Jul 28, 2015: Avraham Pharmaceuticals Announces Successful Second Interim Results in Phase 2b Study of Ladostigil for the Treatment of Mild Cognitive Impairment
Jul 14, 2015: CereSpir Obtains New Patent From USPTO Covering the Optimal Synthetic Route for Commercial Manufacture of CSP-1103 in Late Stage Development to Slow the Progression of Mild Cognitive Impairment Due to Alzheimers Disease
Jul 01, 2015: CereSpir Submits Special Protocol Assessment Request to FDA for a Phase 3 Clinical Trial to Test the Ability of CSP-1103 to Slow the Progression of Mild Cognitive Impairment Due to Alzheimers Disease
Jul 08, 2014: Avraham Pharmaceuticals Announces Successful Interim Results in Phase 2b Study of Ladostigil for the Treatment of MCI
Jul 26, 2013: CERESPIR INCORPORATED IS PLEASED WITH POSITIVE INTERIM PHASE 2 RESULTS FOR CHF 5074 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT, PRESENTED BY CHIESI AT THE AAIC 2013 MEETING IN BOSTON
May 17, 2012: Avraham Initiates Phase II Ladostigil Study For Treatment Of Mild Cognitive Impairment
Apr 14, 2010: Alzheimer Drug Co Avraham Pharmaceuticals Raises $9m
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables


Number of Products under Development for Mild Cognitive Impairment, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Mild Cognitive Impairment - Pipeline by AbbVie Inc, H2 2018
Mild Cognitive Impairment - Pipeline by AgeneBio Inc, H2 2018
Mild Cognitive Impairment - Pipeline by Avraham Pharmaceuticals Ltd, H2 2018
Mild Cognitive Impairment - Pipeline by Biogen Inc, H2 2018
Mild Cognitive Impairment - Pipeline by CereSpir Inc, H2 2018
Mild Cognitive Impairment - Pipeline by Eisai Co Ltd, H2 2018
Mild Cognitive Impairment - Pipeline by Eli Lilly and Co, H2 2018
Mild Cognitive Impairment - Pipeline by IntelGenx Corp, H2 2018
Mild Cognitive Impairment - Pipeline by Neuron Biopharma SA, H2 2018
Mild Cognitive Impairment - Pipeline by Octapharma AG, H2 2018
Mild Cognitive Impairment - Pipeline by Pfizer Inc, H2 2018
Mild Cognitive Impairment - Pipeline by Sage Therapeutics Inc, H2 2018
Mild Cognitive Impairment - Pipeline by SBI Pharmaceuticals Co Ltd, H2 2018
Mild Cognitive Impairment - Pipeline by Therapix Biosciences Ltd, H2 2018
Mild Cognitive Impairment - Dormant Projects, H2 2018
Mild Cognitive Impairment - Dormant Projects, H2 2018 (Contd..1), H2 2018
Mild Cognitive Impairment - Discontinued Products, H2 2018

List Of Figures


Number of Products under Development for Mild Cognitive Impairment, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Mild Cognitive Impairment - Pipeline Review, H2 2018

Mild Cognitive Impairment - Pipeline Review, H2 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Mild Cognitive Impairment - Pipeline Review, H2 2018, provides an overview of the

USD 2000View Report

Global Bright Mild Steel Bars Industry Market Research Report

The Bright Mild Steel Bars market revenue was xx.xx Million USD in 2013, grew to xx.xx Million USD in 2017, and will reach xx.xx Million USD in 2023, with a

USD 2960View Report

Global Cognitive Impairment Disorders Drug Market Research Report 2018

Cognitive Impairment Disorders Drug Report by Material, Application, and Geography Global Forecast to 2022 is a professional and in-depth research report on the worlds major regional market conditions, focusing

USD 2850View Report

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2018

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2

USD 2000View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : Sep 2018
No. of Pages :106
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube